Comparative Pharmacology
Head-to-head clinical analysis: BENZOYL PEROXIDE AND CLINDAMYCIN PHOSPHATE versus CLEOCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZOYL PEROXIDE AND CLINDAMYCIN PHOSPHATE versus CLEOCIN.
BENZOYL PEROXIDE AND CLINDAMYCIN PHOSPHATE vs CLEOCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzoyl peroxide: oxidizes bacterial proteins via free radical release, reducing Cutibacterium acnes; keratolytic and comedolytic. Clindamycin phosphate: inhibits bacterial protein synthesis by binding to 50S ribosomal subunit, bacteriostatic against C. acnes.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide bond formation.
Topical: Apply a thin film to affected areas twice daily (morning and evening). Each gram of gel contains 50 mg benzoyl peroxide and 10 mg clindamycin phosphate (as clindamycin).
150-450 mg orally every 6 hours; 300-600 mg IM or IV every 6-8 hours; maximum 4.8 g/day IV.
None Documented
None Documented
Clindamycin terminal elimination half-life is 2-4 hours in adults; benzoyl peroxide has minimal systemic absorption, so half-life is not clinically relevant.
2-3 hours in adults with normal renal function; prolonged to 8-12 hours in severe hepatic impairment; dialyzable but not clinically used for Clostridium difficile infection.
Benzoyl peroxide is metabolized to benzoic acid, which is excreted in urine as hippuric acid; clindamycin phosphate is hydrolyzed to clindamycin, which undergoes hepatic metabolism with about 10% excreted unchanged in urine, 3.6% in feces as active drug, and the remainder as metabolites.
Approximately 10% renal as active drug and metabolites, 90% fecal/biliary via enterohepatic circulation; <1% unchanged in urine.
Category A/B
Category C
Lincosamide Antibiotic
Lincosamide Antibiotic